Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2006-10-17
2006-10-17
Haddad, Maher M. (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S154100, C424S173100, C530S387300, C530S388230
Reexamination Certificate
active
07122183
ABSTRACT:
The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNFα inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNFα inhibitors.
REFERENCES:
patent: 5304635 (1994-04-01), Imam et al.
patent: 5480981 (1996-01-01), Goodwin et al.
patent: 5670527 (1997-09-01), Adams et al.
patent: 5677430 (1997-10-01), Goodwin et al.
patent: 5840869 (1998-11-01), Mosley et al.
patent: 0460846 (1991-12-01), None
patent: WO 99/40187 (1999-08-01), None
patent: WO 03/043583 (2003-05-01), None
Bengtsson Å. et al, “Not only Th2 cells but also Th1 and Th0 cells express CD30 after activation,”J. Leukoc. Biol.58:683-689 (1995).
Blom AB et al., “Immune complexes, but not streptococcal cell walls or zymosan, cause chronic arthritis in mouse strains susceptible for collagen type II auto-immune arthritis,”Cytokine1999; 11:1046-1056, XP-001089856.
Caligaris-Cappio F. et al., “Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity,”Clin. Exp. Rheumatol.13:339-343 (1995).
Durkop H. et al., “Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's Disease,”Cell68:421-427 (1992).
Erickson S. L. et al., “Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice,”Nature372:560-563 (1994).
Gilfillan M. C. et al., “Expression of the costimulatory receptor CD30 is regulated by both CD28 amd cytokines,”J. Immunol.160:2180-2187 (1998).
Gruss H-J et al., “Biological roles of CD30 ligand in CD30+ malignant lymphomas and T cell-dependent immune responses,”Exp Hematol(Charlottesville), 1995, 23:8551, XP008005895.
Hamann D. et al., “CD30 expression does not discriminate between human Th1- and Th2-type T cells,”J. Immunol.156:1387-1391 (1996).
Horie R. and Watanabe T., “CD30: expression and function in health disease,”Semin. Immunol.10:457-470 (1998).
Koon H. B. and Junghans R. P., “Anti-CD30 antibody-based therapy,”Curr. Opin. Oncol.12:588-593 (2000).
Körner H. et al., “Tumor necrosis factor blockade in actively induced experimental autoimmune encephalomyelitis prevents clinical disease despite activated T cell infiltration to the central nervous system,”Eur. J. Immunol.27:1973-1981 (1997).
Körner H. et al., “Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defines by gene targeting,”J. Exp. Med.186(9):1585-1590 (1997).
Kurts C. et al., “Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells,”Nature398:341-344 (1999).
Liu A. Y. et al., “Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells,”Proc. Natl. Acad. Sci. USA84:3439-3443 (1987).
Marino M. W. et al., “Characterizatioon of tumor necrosis factor-deficient mice,”Proc. Natl. Acad. Sci. USA94:8093-8098 (1997).
Mendel I. et al., “A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-dbmice: fine specificity and T cell receptor Vβ expression of encephalitogenic T cells,”Eur. J. Immunol.25:1951-1959 (1995).
Mori L. et al., “Attenuation of collagn-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice,”J. Immunol.157:3178-3182 (1996).
Nakamura T. et al., “Reciprocal regulation of CD30 expression on CD4+T cells by IL-4 and IFN-γ,”J. Immunol.158:2090-2098 (1997).
Peschon J. J. et al., “TNF receptor-deficient mice reveal divergent roles for P55 and P75 in several models of inflammation,”J. Immunol.160:943-952 (1998).
Pfeffer K. et al., “Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb toL. monocytogenesinfection,”Cell73:457-467 (1993).
Riechmann L. et al., “Reshaping human antibodies for therapy,”Nature332:323-327 (1988).
Romagnani S. et al., “CD30 and type 2 T helper (Th2) responses,”J. Leukoc. Biol.57:726-730 (1995).
Romagnani S., “Biology of human TH1 and TH2 cells,”J. Clin. Immunol.15(3):121-129 (1995).
Rothe J. et al., “Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection byListeria monocytogenes,” Nature364:798-802 (1993).
Smith C. A. et al., “CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines to TNF,”Cell73:1349-1360 (1993).
Sundarapandiyan K. et al., “Bispecific antibody-mediated destruction of Hodgkin's lymphoma cells,”J. Immunol. Methods248:113-123 (2001).
Wiley S. R. et al., “Reverse signaling via CD30 ligand,”J. Immunol.157:3635-3639 (1996).
Winter G. and Harris W. J., “Antibody-based therapy,”TiPS14:139-143 (1993).
Yamamoto J. et al., “CD30 expression on circulating memory CD4+T cells as a TH2-dominated situation in patients with atopic dermatitis,”Allergy55:1011-1018 (2000).
Barone Dauphine S.
Kennedy Mary K.
Mohler Kendall M.
Peschon Jacques J.
Pluenneke John D.
Haddad Maher M.
Immunex Corporation
Perkins Patricia Anne
LandOfFree
Methods for treating autoimmune and chronic inflammatory... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating autoimmune and chronic inflammatory..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating autoimmune and chronic inflammatory... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3620664